AI Business LensTHE BUSINESS OF AI, FOR PEOPLE WHO TEACH IT OR LEARN FROM IT
MedCity News · September 29, 2026 · On the brief until October 13, 2026

DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens

MedicineHealth AdministrationBiomedical Engineering
THE AI ANGLE
Recommending insulin doses from continuous glucose monitor data

The FDA cleared DreaMed's MODI app to recommend insulin doses for people with Type 2 diabetes on both basal and fast-acting injection plans. The software analyzes continuous glucose monitor data and adjusts doses between office visits without requiring provider review for each change. This gives clinicians and health systems a way to adjust complex regimens without long delays between appointments.

Summary written by AI Business Lens with an AI model from the article at medcitynews.com. It is not the article, and the publisher has not reviewed it. For publishers.

THE TEACHING ANGLE
Clinicians and engineers must balance algorithm autonomy against patient safety when dosing a drug that can cause coma or death.

Read the original at medcitynews.com   Generate teaching or study materials

Instructors get discussion guides, assignments, and mini-cases. Students and readers get a plain summary, points to raise, an exercise, and a self-check. All built from the full article. A free account saves stories and gives you three generations. Stories stay on the brief for 14 days. After that this page keeps the link to the original.

More in Medicine